CRISPR Therapeutics AG

CRSP65

$47.25arrow_drop_up0.89%$0.42

CRSP65

$47.25

arrow_drop_up0.89%$0.42

Performance History

Key Stats
Open	$47.61
Prev. Close	$46.85
EPS	-2.79
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	46.37	48.68
52 Week Range	37.55	91.10

Ratios







EPS	-2.79

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG (CRSP) is a leading gene-editing company that focuses on developing transformative therapies using CRISPR-Cas9 technology. The company's mission is to cure serious diseases by editing the genes responsible for these conditions. CRISPR-Cas9 is a unique tool that allows scientists to precisely edit DNA, correcting or modifying genes to treat genetic disorders and potentially eradicate certain diseases. CRISPR Therapeutics AG is at the forefront of this revolutionary technology, leading the way in advancing gene-editing therapies.

One of the key advantages of CRISPR-Cas9 is its versatility and precision. It can be used to target and edit specific genes, opening up possibilities for treating a wide range of genetic diseases. CRISPR Therapeutics AG is leveraging this technology to develop treatments for various conditions, including rare genetic disorders, cancer, and even infectious diseases like HIV. The potential of CRISPR-Cas9 is immense, and CRISPR Therapeutics AG is dedicated to harnessing its power for the benefit of patients worldwide.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Samarth Kulkarni Ph.D.
Headquarters: Zug
Employees: 458
Exchange: NASDAQ

Keep an eye on CRISPR Therapeutics AG

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is CRISPR Therapeutics AG's (CRSP) price per share?

The current price per share for CRISPR Therapeutics AG (CRSP) is $47.25. The stock has seen a price change of $0.42 recently, indicating a 0.9% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for CRISPR Therapeutics AG (CRSP)?

For CRISPR Therapeutics AG (CRSP), the 52-week high is $91.1, which is 92.8% from the current price. The 52-week low is $37.55, the current price is 25.83% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is CRISPR Therapeutics AG (CRSP) a growth stock?

CRISPR Therapeutics AG (CRSP) has shown an average price growth of -6.65% over the past three years. It has received a score of 27 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying CRISPR Therapeutics AG as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is CRISPR Therapeutics AG (CRSP) stock price performance year to date (YTD)?

As of the latest data, CRISPR Therapeutics AG (CRSP) has a year-to-date price change of -28.47%. Over the past month, the stock has experienced a price change of -3.57%. Over the last three months, the change has been -1.25%. Over the past six months, the figure is -15.12%. Looking at a longer horizon, the five-year price change stands at -19.27%.

help

Is CRISPR Therapeutics AG (CRSP) a profitable company?

CRISPR Therapeutics AG (CRSP) has a net income of -$153.61M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 64.91% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -18.29K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $371.21M, although specific revenue growth data is currently not available. The gross profit is $240.96M. Operating income is noted at -$222.54M. Furthermore, the EBITDA is -$313.08M.

help

What is the market capitalization of CRISPR Therapeutics AG (CRSP)?

CRISPR Therapeutics AG (CRSP) has a market capitalization of $4.03B. The average daily trading volume is 47.24, indicating the stock's liquidity and investor engagement.